Clinical trials: Recurrent Tumor
Bladder Carcinoma, Recurrent Bladder Carcinoma
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
This randomized phase II trial studies how well erlotinib hydrochloride works in treating patients with bladder cancer undergoing surgery.
- Trial name
- NCT02169284
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Rectal Cancer
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer
The purpose of this trial is to determine the maximum tolerated dose (MTD) of hypofractionated IMPT for the reirradiation of locoregionally recurrent rectal cancer.
- Trial name
- IMPARC (NCT04827732)
- Testing
- Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy, MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Brain Tumor, Central Nervous System Tumor
Radiation Therapy in Treating Young Patients With Gliomas
RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00238264
- Testing
- radiation therapy
- Where
- 145 sites in United States, Australia and 4 more
- Volunteers
- 92 people
- Sponsor
- Children's Oncology Group
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial studies the side effects and how well nintedanib works in treating patients with endometrial cancer that has come back.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01225887
- Testing
- Nintedanib
- Where
- 59 sites in United States
- Volunteers
- 37 people
- Sponsor
- Gynecologic Oncology Group
Lung Cancer
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00519831
- Testing
- cetuximab, vinflunine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
This phase I trial tests the safety, side effects, and determination of the best dose of uproleselan in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia, myelodysplastic syndrome or…
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT05146739
- Testing
- Cytarabine, Fludarabine, Leucovorin
- Where
- 19 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Panitumumab plus bortezomib for colon cancer
- Trial name
- NCT01504477
- Testing
- Panitumumab and bortezomib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Georgetown University
High Grade Glioma, BRAF V600E
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.
- Conditions
- High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma
- Trial name
- BRAF (NCT03973918)
- Testing
- Encorafenib, Binimetinib, Research Bloods
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sarcoma
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
This study will examine the safety and effectiveness of stem cell transplantation for treating patients with sarcomas (tumors of the bone, nerves, or soft tissue).
- Trial name
- NCT00043979
- Testing
- F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in…
- Trial name
- NCT00723203
- Testing
- panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Liver Cancer
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00881751
- Testing
- bevacizumab, erlotinib hydrochloride, sorafenib tosylate
- Where
- 6 sites in United States
- Volunteers
- 95 people
- Sponsor
- Medical University of South Carolina
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Participants with recurrent or metastatic (R/M) squamous cell cancer of the head and neck (HNSCC) will be randomly assigned to receive pembrolizumab monotherapy [pembro mono], pembrolizumab plus chemotherapy with a platinum-based…
- Trial name
- NCT02358031
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Volunteers
- 882 people
- Sponsor
- Merck Sharp & Dohme LLC
Adult Solid Neoplasm, Childhood Solid Neoplasm
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
This phase I/II trial studies the side effects and best dose of talazoparib and temozolomide and to see how well they work in treating younger patients with tumors that have not responded to previous treatment (refractory) or…
- Conditions
- Adult Solid Neoplasm, Childhood Solid Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT02116777
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Where
- 22 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Adenoid Cystic Carcinoma
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
This research study is studying immunotherapy with or without radiation therapy as a possible treatment for adenoid cystic carcinoma. The immunotherapy involved in this study is: Pembrolizumab (MK-3475 or KEYTRUDA).
- Trial name
- NCT03087019
- Testing
- Radiation, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Fallopian Tube Cancer, Ovarian Cancer
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Lenalidomide may stop the growth of cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00903630
- Testing
- Lenalidomide, liposomal doxorubicin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well sorafenib tosylate and yttrium Y 90 glass microspheres work in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Recurrent Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT01900002
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Melanoma, Stage IV Melanoma
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
This randomized phase II trial is studying how well giving sorafenib together with either temsirolimus or tipifarnib works in treating patients with stage IV melanoma that cannot be removed by surgery.
- Trial name
- NCT00281957
- Testing
- sorafenib tosylate, tipifarnib, temsirolimus
- Where
- 173 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal…
- Trial name
- NCT02438722
- Testing
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Where
- 638 sites in United States
- Volunteers
- 174 people
- Sponsor
- SWOG Cancer Research Network
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Trial name
- NCT02879695
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
This randomized phase II trial is studying topotecan to see how well it works when given with or without aflibercept in treating patients with extensive-stage small cell lung cancer.
- Trial name
- NCT00828139
- Testing
- ziv-aflibercept, topotecan hydrochloride
- Where
- 257 sites in United States
- Volunteers
- 189 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.